Weekly Recap

IPO Boutique comments on Allogene Therapeutics, Inc. (ALLO)

This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]

Weekly Secondary Recap (11.17.17)

IPO BOUTIQUE is one of the few syndicate services that provides ratings on all secondary offerings (Spots, blocks, marketed). We use our database of historical performances, underwriter trends and more than 40 years playing the syndicate service to give our clients a leg up. We meticulously keep records of our ratings. If interested please click below[…]

IPO Recap: Athenex up 25+% in opening week

SIGN UP FOR IPO BOUTIQUE’S FREE NEWSLETTER   Two IPOs came to market this week with mixed success.   Athenex Inc (Nasdaq: ATNX) priced a full-size deal at the low-end of the range, $11.00, and opened with a $1.00 premium at first trade. The heavily insider-backed offering traded well in its opening week as ‘ATNX’[…]

Two Healthcare IPOs on tap for week ahead

This past week two IPOs debuted, one IPO updated terms and two new deals were filed. Two IPOs came to market with far different levels of success. ShotSpotter, Inc (Nasdaq: SSTI) priced 2.8mm shares at the midpoint of the range, $11.00, and opened 10.9% higher with a first trade of $12.20. The Roth Capital underwritten[…]

IPO Weekly Recap – Pair of IPOs Fail to Come to Market

This past week zero IPOs debuted, ten updated terms and two new deals were filed. There were two IPOs on the schedule to debut this week, however, neither had the demand needed to successfully come to market. According to the underwriter, the Xtera Communications (Nasdaq: XCOM) deal has been pushed to next week. Please refer[…]

IPO Weekly Recap – 8.07.2015

This past week five IPOs debuted, one updated terms and one new deal was filed. The two biotech deals that came to market were well-received by the IPO market. Aimmune Therapeutics (Nasdaq: AIMT) priced at the high end of the range, $16.00, and opened with a $1.50 premium. ‘AIMT’ traded as high as $27.00 on[…]

Scroll to top
error: Content is protected !!